Across TCGA pan-cancer cohorts, SNHG16 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SNHG16 data layer compared with 24 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher SNHG16 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SNHG16 expression acts as an unfavorable survival marker.
SKCM are the cancer types where SNHG16 Mutation most reproducibly stratifies survival.